ArticleOxford medical case reports2025
Primary renal lymphoma in a uremic patient.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary renal lymphoma is a rare renal malignancy, and its occurrence in patients undergoing maintenance haemodialysis is even more uncommon. Herein, we report the case of a 57-year-old woman undergoing maintenance haemodialysis, presenting with gross haematuria. After performing enhanced magnetic resonance imaging, positron emission tomography-computed tomography, and a kidney biopsy, a diffuse large B-cell lymphoma was detected. She was subsequently treated with five cycles of a modified R-CHOP regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, and achieved partial remission, as evidenced by an abdominal computed tomography scan. At the 15-month follow-up, no further enlargement or metastasis of the residual tumour was evident. We emphasize that the clinical manifestations of primary renal lymphoma (PRL) resemble those of renal cell carcinoma, necessitating an imaging and biopsy-based differential diagnosis to avoid misdiagnosis. Although PRL has a highly aggressive phenotype and is associated with high mortality, early diagnosis and appropriate treatment can improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.